Perrigo Company plc is an American Irish registered manufacturer of private label over-the-counter pharmaceuticals.
| Revenue (TTM) | $4.14B |
| Gross Profit (TTM) | $1.38B |
| EBITDA | $615.50M |
| Operating Margin | 3.84% |
| Return on Equity | -48.70% |
| Return on Assets | 1.97% |
| Revenue/Share (TTM) | $29.83 |
| Book Value | $18.14 |
| Price-to-Book | 0.72 |
| Price-to-Sales (TTM) | 0.43 |
| EV/Revenue | 1.135 |
| EV/EBITDA | 8.41 |
| Quarterly Earnings Growth (YoY) | -63.60% |
| Quarterly Revenue Growth (YoY) | -3.20% |
| Shares Outstanding | $138.37M |
| Float | $138.08M |
| % Insiders | 0.40% |
| % Institutions | 120.66% |
Volatility is currently expanding
Perrigo Company remains substantially undervalued, with a Buy rating justified by strong income and growth potential. Recent quarterly EPS and revenue beats, coupled with market share gains, signal improving fundamentals despite a soft OTC market. Management's focus on cost control, debt reduction, and dividend growth underpins a compelling 16–21% expected annual total return.
Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two companies is the best option for those looking for undervalued stocks?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
PRGO tops Q2 EPS estimates as Infant Formula sales jump, helping offset softer demand and divestiture impacts while the company reaffirms 2026 guidance.
Perrigo Company plc (PRGO) Q2 2026 Earnings Call Transcript
The headline numbers for Perrigo (PRGO) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Perrigo (PRGO) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.57 per share a year ago.
Execution of Three-S plan driving continued improvement in underlying business fundamentals, including market share growth in U.S. store-brand OTC and key European brands Streamlined portfolio through completion of Dermacosmetics divestiture and continuing strategic reviews of Infant Formula and Oral Care businesses Reaffirmed full-year 2026 outlook with sequentially stronger second-half performance DUBLIN, Aug. 5, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced financial results from continuing operations for the second quarter ended June 27, 2026. "We continued to execute our Three-S plan in the second quarter, strengthening areas of the business within our control, improving operational performance, streamlining our portfolio, and further reducing debt," said Albert Manzone, Interim President and Chief Executive Officer.
DUBLIN, July 30, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that its Board of Directors has approved a quarterly dividend of $0.29 per share, or $1.16 per share on an annualized basis. The cash dividend is payable on September 15, 2026, to shareholders of record on August 28, 2026.
DUBLIN, July 29, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra are scheduled to present at the Canaccord 46th Annual Growth Conference, on Wednesday, August 12th at 10:30 AM EDT. The webcast can be accessed on the Perrigo website at http://perrigo.investorroom.com/events-webcasts.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PRGO and any ticker you trade — then tracks every position and per-strategy win rate.
